Nanoparticle technology for treatment of Parkinson's disease: the role of surface phenomena in reaching the brain

Drug Discovery Today

Volumn 20, Issue 7, 2015, Pages 824-837

  Leyva Gómez, Gerardo ^a   Cortés, Hernán ^a   Magaña, Jonathan J ^a   Leyva García, Norberto ^a   Quintanar Guerrero, David ^b   Florán, Benjamín ^c  

^a INSTITUTO NACIONAL DE REHABILITACIÓN   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^c DEPARTAMENTO DE FÍSICA   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; ANTIPARKINSON AGENT; CHOLINESTERASE INHIBITOR; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; NANOPARTICLE; NEUROTROPHIC FACTOR; SOLID LIPID NANOPARTICLE; DRUG CARRIER; POLYMER;

ARTICLE; BRAIN; CLINICAL FEATURE; DRUG DELIVERY SYSTEM; HUMAN; NANOTECHNOLOGY; PARKINSON DISEASE; PARTICLE SIZE; PHYSICAL PHENOMENA; POLYMERIZATION; SURFACE PHENOMENA; ZETA POTENTIAL; ANIMAL; BLOOD BRAIN BARRIER; CHEMISTRY; MEDICINAL CHEMISTRY; METABOLISM; NANOMEDICINE; PERMEABILITY; PHARMACEUTICS; PROCEDURES; SOLUBILITY;

ANIMALS; ANTIPARKINSON AGENTS; BLOOD-BRAIN BARRIER; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; HUMANS; NANOMEDICINE; NANOPARTICLES; PARKINSON DISEASE; PERMEABILITY; POLYMERS; SOLUBILITY; TECHNOLOGY, PHARMACEUTICAL;

EID: 84936846086     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2015.02.009     Document Type: Review

References (131)

1. L.M. de Lau, and M. Breteler Epidemiology of Parkinson's disease Lancet Neurol. 5 2006 525 535
2. S.K. Van Den Eeden Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity Am. J. Epidemiol. 157 2003 1015 1022
3. W.G. Meissner Priorities in Parkinson's disease research Nat. Rev. Drug Discov. 10 2011 377 393
4. K.R. Chaudhuri Motor and nonmotor complications in Parkinson's disease: an argument for continuous drug delivery? J. Neural Transm. 120 2013 1305 1320
5. L.V. Kalia Novel nondopaminergic targets for motor features of Parkinson's disease: review of recent trials Mov. Disord. 28 2013 131 144
6. A. Misra Drug delivery to the central nervous system: a review J. Pharm. Pharm. Sci. 6 2003 252 273
7. R. Gabathuler Blood-brain barrier transport of drugs for the treatment of brain diseases CNS Neurol. Disord. Drug Targets 8 2009 195 204
8. F. Stocchi Continuous dopaminergic stimulation and novel formulations of dopamine agonists J. Neurol. 258 2011 S316 S322
9. J.A. Obeso, and W. Olanow Continuing efforts to obtain continuous delivery of levodopa Mov. Disord. 26 2011 2149 2150
10. J. Kreuter Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles) Brain Res. 674 1995 171 174
11. J. Kreuter Drug delivery to the central nervous system by polymeric nanoparticles: what do we know? Adv. Drug Deliv. Rev. 71 2014 2 14
12. G. Linazasoro Potential applications of nanotechnologies to Parkinson's disease therapy Parkinsonism Relat. Disord. 14 2008 383 392
13. E. Garbayo Drug development in Parkinson's disease: from emerging molecules to innovative drug delivery systems Maturitas 76 2013 272 278
14. A. Benazzouz Involvement of dopamine loss in extrastriatal basal ganglia nuclei in the pathophysiology of Parkinson's disease Front. Aging Neurosci. 6 2014 87
15. P.M. Antony The hallmarks of Parkinson's disease FEBS J. 280 2013 5981 5993
16. E. Heremans Freezing of gait in Parkinson's disease: where are we now? Curr. Neurol. Neurosci. Rep. 13 2013 350
17. J. Kulisevsky Enfermedad de Parkinson avanzada. Características clínicas y tratamiento (parte I) Neurología 28 2013 503 521
18. K.R. Chaudhuri, and A. Schapira Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment Lancet Neurol. 8 2009 464 474
19. P. Jenner Parkinson's disease - the debate on the clinical phenomenology, aetiology, pathology and pathogenesis J. Parkinsons Dis. 3 2013 1 11
20. J.W. Langston, and P.A. Ballard Parkinson's disease in a chemist working with 1-methyl-4-phenyl-1,2,5,6- tetrahydropyridine N. Engl. J. Med. 309 1983 310
21. V.N. Uversky Neurotoxicant-induced animal models of Parkinson's disease: understanding the role of rotenone, maneb and paraquat in neurodegeneration Cell Tissue Res. 318 2004 225 241
22. J. Hardy The genetics of Parkinson's syndromes: a critical review Curr. Opin. Genet. Dev. 19 2009 254 265
23. C. Funke Genetics and iron in the systems biology of Parkinson's disease and some related disorders Neurochem. Int. 62 2013 637 652
24. K.M. Lucin, and T. Wyss-Coray Immune activation in brain aging and neurodegeneration: too much or too little? Neuron 64 2009 110 122
25. B.S. Connoly, and A.E. Lang Pharmacological treatment of Parkinson disease: a review JAMA 311 2014 1670 1683
26. M.R. Luquin Levodopa en el tratamiento de la enfermedad de Parkinson: mitos y realidades Rev. Neurol. 55 2012 669 688
27. R. De Vecchis Cabergoline use and risk of fibrosis and insufficiency of cardiac valves. Meta-analysis of observational studies Herz 38 2013 868 880
28. C.W. Olanow, and A.H. Schapira Therapeutic prospects for Parkinson disease Ann. Neurol. 74 2013 337 347
29. F.I. Tarazi Emerging therapies for Parkinson's disease: from bench to bedside Pharmacol. Ther. 144 2014 123 133
30. J. Kreuter Nanoparticles J. Swarbrick, J.C. Boylan, Encyclopedia of Pharmaceutical Technology 1994 Marcel Dekker 165
31. B. Kante Toxicity of polyalkylcyanoacrylate nanoparticles I: free nanoparticles J. Pharm. Sci. 71 1982 786 790
32. I. Limayem, and H. Fessi Purification of nanoparticle suspension by a concentration/diafiltration process Sep. Purif. Technol. 38 2004 1 9
33. C. Freitas, and R.H. Müller Effect of light and temperature on zeta potential and physical stability in solid lipid nanoparticles (SLN) dispersions Int. J. Pharm. 168 1998 221 229
34. S.H. Gohla, and A. Dingler Scaling up feasibility of the production of solid lipid nanoparticles (SLN) Pharmazie 56 2001 61 63
35. R.H. Müller Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art Eur. J. Pharm. Biopharm. 50 2000 161 177
36. W. Abdelwahed Freeze-drying of nanoparticles: formulation, process and storage considerations Adv. Drug Deliv. Rev. 58 2006 1688 1713
37. I.P. Kaur Potential of solid lipid nanoparticles in brain targeting J. Control. Release 127 2008 97 109
38. A. Fundarò Non-stealth and stealth solid lipid nanoparticles (SLN) carrying doxorubicin: pharmacokinetics and tissue distribution after i.v. administration to rats Pharmacol. Res. 42 2000 337 343
39. E. Peira In vitro and in vivo study of solid lipid nanoparticles loaded with superparamagnetic iron oxide J. Drug Target. 11 2003 19 24
40. C.M. Keck, and R.H. Müller Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation Eur. J. Pharm. Biopharm. 62 2006 3 16
41. C. Pinto Reis Nanoencapsulation I. Methods for preparation of drug-loaded polymeric nanoparticles Nanomedicine 2 2006 8 21
42. C. Pinto Reis Nanoencapsulation II. Biomedical applications and current status of peptide and protein nanoparticulate delivery systems Nanomedicine 2 2006 53 65
43. N. Voigt Surfactants, not size or zeta-potential influence blood-brain barrier passage of polymeric nanoparticles Eur. J. Pharm. Biopharm. 87 2014 19 29
44. R.G. Thorne, and C. Nicholson In vivo diffusion analysis with quantum dots and dextrans predicts the width of brain extracellular space Proc. Natl. Acad. Sci. U. S. A. 103 2006 5567 5572
45. 14C-poly(methylmethacrylate) nanoparticles in experimental tumor models Pharm. Res. 18 2001 1613 1619
46. G. Leyva-Gomez Evaluation of the anxiolytic effect produced by clonazepam-solid lipid nanoparticles Lat. Am. J. Pharm. 33 2014 307 314
47. G. Leyva-Gomez Nanoparticle formulation improves the anticonvulsant effect of clonazepam on the pentylenetetrazole-induced seizures: behavior and electroencephalogram J. Pharm. Sci. 103 2014 2509 2519
48. H. Karatas A nanomedicine transports a peptide caspase-3 inhibitor across the blood-brain barrier and provides neuroprotection J. Neurosci. 29 2009 13761 13769
49. P.R. Lockman Nanoparticle surface charges alter blood-brain barrier integrity and permeability J. Drug Target. 12 2004 635 641
50. M.A. Dobrovolskaia Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution Mol. Pharm. 5 2008 487 495
51. M. Lundqvist Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts Proc. Natl. Acad. Sci. U. S. A. 105 2008 14265 14270
52. Darabi, and F. Sahneh Dynamics of nanoparticle-protein corona complex formation: analytical results from population balance equations PLOS ONE 8 2013 e64690
53. Z.J. Deng Nanoparticle-induced unfolding of fibrinogen promotes Mac-1 receptor activation and inflammation Nat. Nanotechnol. 6 2011 39 44
54. M.P. Monopoli Physical-chemical aspects of protein corona: relevance to in vitro and in vivo biological impacts of nanoparticles J. Am. Chem. Soc. 133 2011 2525 2534
55. H.S. Choi Renal clearance of quantum dots Nat. Biotechnol. 25 2007 1165 1170
56. C.D. Walkey, and W.C. Chan Understanding and controlling the interaction of nanomaterials with proteins in a physiological environment Chem. Soc. Rev. 41 2012 2780 2799
57. P. Roach Interpretation of protein adsorption: surface-induced conformational changes J. Am. Chem. Soc. 127 2005 8168 8173
58. T. Cedervall Understanding the nanoparticle-protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles Proc. Natl. Acad. Sci. U. S. A. 104 2007 2050 2055
59. R. Gref 'Stealth' corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption Colloids Surf. B 18 2000 301 313
60. R.C. Rowe Handbook of Pharmaceutical Excipients 2009 Pharmaceutical Press 517 522
61. K. Knop Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives Angew. Chem. Int. Ed. Engl. 49 2010 6288 6308
62. D.E. Owens 3rd, and N.A. Peppas Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles Int. J. Pharm. 307 2006 93 102
63. J.V. Jokerst Nanoparticle PEGylation for imaging and therapy Nanomedicine 6 2011 715 728
64. N. Backmann Sensing surface PEGylation with microcantilevers Beilstein J. Nanotechnol. 1 2010 3 13
65. H. Lee A coarse-grained model for polyethylene oxide and polyethylene glycol: conformation and hydrodynamics J. Phys. Chem. B 113 2009 13186 13194
66. S.M. Moghimi, and J. Szebeni Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties Prog. Lipid Res. 42 2003 463 478
67. A. Vila Transport of PLA-PEG particles across the nasal mucosa: effect of particle size and PEG coating density J. Control. Release 98 2004 231 244
68. G. Fontana Amoxicillin-loaded polyethylcyanoacrylate nanoparticles: influence of PEG coating on the particle size, drug release rate and phagocytic uptake Biomaterials 22 2001 2857 2865
69. A. Vonarbourg Parameters influencing the stealthiness of colloidal drug delivery systems Biomaterials 27 2006 4356 4373
70. J.M. Rabanel Assessment of PEG on polymeric particles surface, a key step in drug carrier translation J. Control. Release 185 2014 71 87
71. A. Abuchowski Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase J. Biol. Chem. 252 1977 3582 3586
72. T. Ishida, and H. Kiwada Accelerated blood clearance (ABC) phenomenon upon repeated injection of PEGylated liposomes Int. J. Pharm. 354 2008 56 62
73. M. Obst, and A. Steinbüchel Microbial degradation of poly(amino acid)s Biomacromolecules 5 2004 1166 1176
74. A.W. Richter, and E. Akerblom Antibodies against polyethylene glycol produced in animals by immunization with monomethoxy polyethylene glycol modified proteins Int. Arch. Allergy Appl. Immunol. 70 1983 124 131
75. Abu, and A.S. Lila The accelerated blood clearance (ABC) phenomenon: clinical challenge and approaches to manage J. Control. Release 172 2013 38 47
76. T. Ishida Injection of PEGylated liposomes in rats elicits PEG-specific IgM, which is responsible for rapid elimination of a second dose of PEGylated liposomes J. Control. Release 112 2006 15 25
77. T. Suzuki Accelerated blood clearance of PEGylated liposomes containing doxorubicin upon repeated administration to dogs Int. J. Pharm. 436 2012 636 643
78. T. Ishida Accelerated blood clearance of PEGylated liposomes following preceding liposome injection: effects of lipid dose and PEG surface-density and chain length of the first-dose liposomes J. Control. Release 105 2005 305 317
79. H. Koide Particle size-dependent triggering of accelerated blood clearance phenomenon Int. J. Pharm. 362 2008 197 200
80. L. Costantino, and D. Boraschi Is there a clinical future for polymeric nanoparticles as brain-targeting drug delivery agents? Drug Discov. Today 17 2012 367 378
81. P. Blasi Lipid nanoparticles for brain targeting II. Technological characterization Colloids Surf. B 110 2013 130 137
82. U. Panzenboeck ABCA1 and scavenger receptor class B, type I, are modulators of reverse sterol transport at an in vitro blood-brain barrier constituted of porcine brain capillary endothelial cells J. Biol. Chem. 277 2002 42781 42789
83. Z. Balazs Uptake and transport of high-density lipoprotein (HDL) and HDL-associated alpha-tocopherol by an in vitro blood-brain barrier model J. Neurochem. 89 2004 939 950
84. S. Wagner Uptake mechanism of ApoE-modified nanoparticles on brain capillary endothelial cells as a blood-brain barrier model PLoS One 7 2012 e32568
85. J. Franco-Pérez, and C. Paz Quinine, a selective gap junction blocker, decreases REM sleep in rats Pharmacol. Biochem. Behav. 94 2009 250 254
86. K. Ulbrich Transferrin- and transferrin-receptor-antibody-modified nanoparticles enable drug delivery across the blood-brain barrier (BBB) Eur. J. Pharm. Biopharm. 71 2009 251 256
87. R. Qiao Receptor-mediated delivery of magnetic nanoparticles across the blood-brain barrier ACS Nano 6 2012 3304 3310
88. L. Gastaldi Solid lipid nanoparticles as vehicles of drugs to the brain: current state of the art Eur. J. Pharm. Biopharm. 87 2014 433 444
89. V.K. Venishetty β-Hydroxybutyric acid grafted solid lipid nanoparticles: a novel strategy to improve drug delivery to brain Nanomedicine 9 2013 388 397
90. R. Gabathuler Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases Neurobiol. Dis. 37 2010 48 57
91. L. Costantino Peptide-derivatized biodegradable nanoparticles able to cross the blood-brain barrier J. Control. Release 108 2005 84 96
92. F.C. Thomas Uptake of ANG1005, a novel paclitaxel derivative, through the blood-brain barrier into brain and experimental brain metastases of breast cancer Pharm. Res. 26 2009 2486 2494
93. G. Tosi Targeting the central nervous system: in vivo experiments with peptide-derivatized nanoparticles loaded with loperamide and rhodamine-123 J. Control. Release 122 2007 1 9
94. R. Prades Delivery of gold nanoparticles to the brain by conjugation with a peptide that recognizes the transferrin receptor Biomaterials 33 2012 7194 7205
95. A. Mathew Curcumin loaded-PLGA nanoparticles conjugated with Tet-1 peptide for potential use in Alzheimer's disease PLOS ONE 7 2012 e32616
96. D. Karkan A unique carrier for delivery of therapeutic compounds beyond the blood-brain barrier PLOS ONE 3 2008 e2469
97. L. Han Peptide-conjugated polyamidoamine dendrimer as a nanoscale tumor-targeted T1 magnetic resonance imaging contrast agent Biomaterials 32 2011 2989 2998
98. A. Trapani Characterization and evaluation of chitosan nanoparticles for dopamine brain delivery Int. J. Pharm. 419 2011 296 307
99. S. Pillay Design, biometric simulation and optimization of a nano-enabled scaffold device for enhanced delivery of dopamine to the brain Int. J. Pharm. 382 2009 277 290
100. E. Esposito Nanoparticulate lipid dispersions for bromocriptine delivery: characterization and in vivo study Eur. J. Pharm. Biopharm. 80 2012 306 314
101. S. Md Bromocriptine loaded chitosan nanoparticles intended for direct nose to brain delivery: pharmacodynamic, pharmacokinetic and scintigraphy study in mice model Eur. J. Pharm. Sci. 48 2012 393 405
102. M.J. Tsai Oral apomorphine delivery from solid lipid nanoparticles with different monostearate emulsifiers: pharmacokinetic and behavioral evaluations J. Pharm. Sci. 100 2011 547 557
103. C.J. Wen Theranostic liposomes loaded with quantum dots and apomorphine for brain targeting and bioimaging Int. J. Nanomed. 7 2012 1599 1611
104. S.H. Hsu Physicochemical characterization and in vivo bioluminescence imaging of nanostructured lipid carriers for targeting the brain: apomorphine as a model drug Nanotechnology 21 2010 405101
105. K.S. Liu Combined strategies of apomorphine diester prodrugs and nanostructured lipid carriers for efficient brain targeting Nanotechnology 23 2012 095103
106. T.L. Hwang Development and evaluation of perfluorocarbon nanobubbles for apomorphine delivery J. Pharm. Sci. 98 2009 3735 3747
107. C.V. Pardeshi Novel surface modified polymer-lipid hybrid nanoparticles as intranasal carriers for ropinirole hydrochloride: in vitro, ex vivo and in vivo pharmacodynamic evaluation J. Mater. Sci. Mater. Med. 24 2013 2101 2115
108. I.G. Kondrasheva Efficacy and safety of nasal administration of "Nano-l-DOPA" based on PLGA nanoparticles Engineering 5 2012 27 29
109. P.Y. Gambaryan Increasing the efficiency of Parkinson's disease treatment using a poly(lactic-co-glycolic acid) (PLGA) based l-DOPA delivery system Exp. Neurobiol. 23 2014 246 252
110. N.C. Ngwuluka Fabrication, modeling and characterization of multi-crosslinked methacrylate copolymeric nanoparticles for oral drug delivery Int. J. Mol. Sci. 12 2011 6194 6225
111. S. Sharma Formulation and characterization of intranasal mucoadhesive nanoparticulates and thermo-reversible gel of levodopa for brain delivery Drug Dev. Ind. Pharm. 40 2014 869 878
112. S. Sadigh-Eteghad Effects of levodopa loaded chitosan nanoparticles on cell viability and caspase-3 expression in PC12 neural like cells Neurosciences 18 2013 281 283
113. X. Yang Controlled-release levodopa methyl ester/benserazide-loaded nanoparticles ameliorate levodopa-induced dyskinesia in rats Int. J. Nanomed. 7 2012 2077 2086
114. H. Jin Mitochondria-targeted antioxidants for treatment of Parkinson's disease: preclinical and clinical outcomes Biochim. Biophys. Acta 1842 2014 1282 1294
115. N.K. Swarnakar Oral bioavailability, therapeutic efficacy and reactive oxygen species scavenging properties of coenzyme Q10-loaded polymeric nanoparticles Biomaterials 32 2011 6860 6874
116. B.K. Nanjwade Formulation and characterization of nanostructured lipid carrier of ubiquinone (Coenzyme Q10) J. Biomed. Nanotechnol. 9 2013 450 460
117. S. Onoue Biopharmaceutical characterization of nanocrystalline solid dispersion of coenzyme Q10 prepared with cold wet-milling system Eur. J. Pharm. Sci. 53 2014 118 125
118. S.A. Joshi Rivastigmine-loaded PLGA and PBCA nanoparticles: preparation, optimization, characterization, in vitro and pharmacodynamic studies Eur. J. Pharm. Biopharm. 76 2010 189 199
119. K. Nagpal Optimization of brain targeted chitosan nanoparticles of rivastigmine for improved efficacy and safety Int. J. Biol. Macromol. 59 2013 72 83
120. R. Huang Neuroprotection in a 6-hydroxydopamine-lesioned Parkinson model using lactoferrin-modified nanoparticles J. Gene Med. 11 2009 754 763
121. M.M. Migliore Neurotrophic and neuroprotective efficacy of intranasal GDNF in a rat model of Parkinson's disease Neuroscience 274 2014 11 23
122. D. Martinez-Fong NTS-Polyplex: a potential nanocarrier for neurotrophic therapy of Parkinson's disease Nanomedicine 8 2012 1052 1069
123. M.N. Tiwari Nicotine-encapsulated poly(lactic-co-glycolic) acid nanoparticles improve neuroprotective efficacy against MPTP-induced parkinsonism Free Radic. Biol. Med. 65 2013 704 718
124. K. Hu Lactoferrin conjugated PEG-PLGA nanoparticles for brain delivery: preparation, characterization and efficacy in Parkinson's disease Int. J. Pharm. 415 2011 273 283
125. Z. Wen Odorranalectin-conjugated nanoparticles: preparation, brain delivery and pharmacodynamic study on Parkinson's disease following intranasal administration J. Control. Release 151 2011 131 138
126. M.S. Muthu, and S. Singh Studies on biodegradable polymeric nanoparticles of risperidone: in vitro and in vivo evaluation Nanomedicine 3 2008 305 319
127. M.S. Muthu PLGA nanoparticle formulations of risperidone: preparation and neuropharmacological evaluation Nanomedicine 5 2009 323 333
128. C. Bulmer Production and characterization of novel chitosan nanoparticles for controlled release of rHu-Erythropoietin Biochem. Eng. 68 2012 61 69
129. L. Klingelhoefer, and H. Reichmann Dementia - the real problem for patients with Parkinson's disease Basal Ganglia 4 2014 9 13
130. S.H. Fox Non-dopaminergic treatments in development for Parkinson's disease Lancet Neurol. 7 2008 927 938
131. H. Mochizuki Parkin gene therapy Parkinsonism Relat. Disord. 15 2009 S43 S45